- Home
- CCIX vs ATYR Comparison
CCIX vs ATYR Comparison
Compare CCIX & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIX
- ATYR
- Stock Information
- Founded
- CCIX 2023
- ATYR 2005
- Country
- CCIX United States
- ATYR United States
- Employees
- CCIX N/A
- ATYR N/A
- Industry
- CCIX
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCIX
- ATYR Health Care
- Exchange
- CCIX Nasdaq
- ATYR Nasdaq
- Market Cap
- CCIX 386.1M
- ATYR 451.3M
- IPO Year
- CCIX 2024
- ATYR 2015
- Fundamental
- Price
- CCIX $10.53
- ATYR $5.83
- Analyst Decision
- CCIX
- ATYR Strong Buy
- Analyst Count
- CCIX 0
- ATYR 6
- Target Price
- CCIX N/A
- ATYR $20.20
- AVG Volume (30 Days)
- CCIX 79.5K
- ATYR 5.4M
- Earning Date
- CCIX 01-01-0001
- ATYR 08-12-2025
- Dividend Yield
- CCIX N/A
- ATYR N/A
- EPS Growth
- CCIX N/A
- ATYR N/A
- EPS
- CCIX 0.34
- ATYR N/A
- Revenue
- CCIX N/A
- ATYR N/A
- Revenue This Year
- CCIX N/A
- ATYR $551.06
- Revenue Next Year
- CCIX N/A
- ATYR $1,874.58
- P/E Ratio
- CCIX $30.92
- ATYR N/A
- Revenue Growth
- CCIX N/A
- ATYR N/A
- 52 Week Low
- CCIX $10.00
- ATYR $1.67
- 52 Week High
- CCIX $11.66
- ATYR $7.10
- Technical
- Relative Strength Index (RSI)
- CCIX N/A
- ATYR 54.71
- Support Level
- CCIX N/A
- ATYR $5.15
- Resistance Level
- CCIX N/A
- ATYR $7.10
- Average True Range (ATR)
- CCIX 0.00
- ATYR 0.55
- MACD
- CCIX 0.00
- ATYR -0.00
- Stochastic Oscillator
- CCIX 0.00
- ATYR 37.44
About CCIX Churchill Capital Corp IX Ordinary Shares
Churchill Capital Corp IX is a blank check company.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.